Rybelsus Pill Shows Significant Cardiovascular Benefits
Tap title to read story
Novo Nordisk announced that its oral diabetes drug, Rybelsus, demonstrated significant cardiovascular benefits in a late-stage trial. The four-year study showed a 14% reduction in cardiovascular death, heart attack, and stroke risk compared to a placebo in patients with diabetes and heart disease. This finding could expand Rybelsus's approval to include cardiovascular risk reduction, offering a convenient alternative to injectable treatments like Ozempic and Wegovy, which share the same active ingredient, semaglutide. The most common side effects were gastrointestinal issues, similar to injectable semaglutide. The company has already submitted applications for expanded approval in the US and EU.
JQJO Editorial Desk · Human reviewed · AI assisted. Report a correction.